USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
30 Mar 2022 | 02:45 PM GMT

DTx in Mental Health: measuring evidence & outcomes

Anchored by:

Kris Karson
SVP, Corporate Development
ATROPOS HEALTH
Aahuti Rai
NED, Advisor & Venture Partner
FOUR POINTS HEALTH | CONDUIT CONNECT

Participants:

Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Kris Karson SVP, Corporate DevelopmentAtropos Health
Kris Karson
SVP, Corporate DevelopmentAtropos Health
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Celine Vignal Co-FounderNeurodigitX
Celine Vignal
Co-FounderNeurodigitX
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Kurt Waldhuetter Founder & PresidentStellume Lighting Co
Kurt Waldhuetter
Founder & PresidentStellume Lighting Co
Laurent Morlet Sr. Director Therapeutic, R&D Business TechJohnson & Johnson
Laurent Morlet
Sr. Director Therapeutic, R&D Business TechJohnson & Johnson
Nina Kiwit Gr�nderinMindAhead
Nina Kiwit
Gr�nderinMindAhead
NK
Nina Kiwit CEORoX Health
NK
Nina Kiwit
CEORoX Health
Robert Cuyler Chief Clinical OfficerFreespira
Robert Cuyler
Chief Clinical OfficerFreespira
Swatee Surve CEO & FounderLitesprite
Swatee Surve
CEO & FounderLitesprite
YS
Yifat Segev EnterprenueraMoon
YS
Yifat Segev
EnterprenueraMoon

About this Meeting

Are you working on the evidence generation strategy of DTx products in Mental Health? Do you want to hear from others’ experiences? Keep reading, this session is for you! 

Mental health is an area ripe for DTx given the lack of pharmacological treatments available and evidence showing that therapy is more effective than drugs for certain indications (e.g. anxiety). Showing meaningful evidence to the different stakeholders is one of the ingredients of success. However, given the novelty of the DTx industry and the lack of standards, building the right evidence strategy for DTx can be challenging. Join this meeting to have a peer-to-peer discussion on this topic. More specifically, we will talk about the following: 

  • Do’s & Don’ts when building the evidence generation strategy for DTx in mental health. What are the factors that determine the best strategy (PDT vs. nPDT, disease severity, future routes to market, etc)? 
  • Best practices in the clinical study design (comparators, sample size, recruitment and retention strategies, case studies vs. observational vs. RCTs) 
  • Small companies often struggle to find the resources to generate the evidence required by the different stakeholders. What are the most cost-efficient ways to generate the evidence needed? Can partnerships ease this process?